Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
26-27 May, 2025
i-Cancer Congressi-Cancer Congress
Not Confirmed
Not Confirmed
26-27 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
26-27 May, 2025
i-Cancer Congressi-Cancer Congress
Industry Trade Show
Not Confirmed
26-27 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
13 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biocity-biopharmaceutics-co-ltd-announces-clinical-collaboration-to-evaluate-bc3195-in-combination-with-keytruda-pembrolizumab-in-patients-with-locally-advanced-or-metastatic-solid-tumors-302400770.html
25 Feb 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/biocitys-eta-antagonist-reduces-proteinuria-phase-2-trial-diabetic-kidney-disease
25 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biocity-announces-its-selective-endothelin-type-a-receptor-antagonist-sc0062-met-the-primary-endpoint-in-diabetic-kidney-disease-dkd-in-a-phase-2-trial-2-succeed-302384313.html
14 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biocity-will-present-the-late-breaking-clinical-trial-data-of-its-eta-selective-antagonist-sc0062-at-the-american-society-of-nephrology-asn-2024-with-simultaneous-publication-of-the-trial-data-in-the-journal-of-the-american-soci-302274975.html
26 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/breakthrough-therapy-designation-btd-for-biocitys-sc0062-a-selective-endothelin-type-a-eta-antagonist-granted-by-national-medical-products-administration-for-iga-nephropathy-igan-with-proteinuria-302259663.html
23 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/impressive-preliminary-objective-response-rates-orr-of-36-in-nsclc-and-80-in-egfrmut-nsclc-interim-results-of-a-phase-1-study-of-bc3195-a-first-in-class-adc-targeting-cdh3-presented-by-biocity-at-esmo-2024-302255439.html
ABOUT THIS PAGE